CA-EOS-BIOSCIENCES-INC
Eos Biosciences, Inc. , a bio-targeted nanomedicines company developing a novel nanobiologic particle drug delivery platform technology (Eosomes), and a proprietary oncology-specific product pipeline, announced that the U.S. Patent and Trademark Office has now issued Eos Biosciences a second patent, U.S. Patent No. 9,789,201, for Eos-001 , the company’s HER3-targeted Eosome with doxorubicin payload.
Omar Haffar , Ph.D., Founder, President and Chief Executive Officer, commented, “This is a very exciting time for Eos Biosciences. In addition to expanding and solidifying our patent portfolio, we are making very significant progress on the pre-clinical development and scale-up manufacturing of our products.” Dr. Haffar continued, “We are also implementing a strategic expansion of our product pipeline into immuno-oncology, and the application of Eosomes to other high impact disease areas, such as CNS. We expect to report positive progress in these and other areas in the near future.”
About Eos-001
Eos-001
is a proof-of-concept proprietary product in preclinical development,
intended to address Triple Negative Breast Cancer (TNBC) and HER2+
breast cancer resistant or nonresponsive to first line therapies. HER3
is over-expressed on TNBC and many types of HER2+
metastatic
and drug-resistant solid tumors.
About Eosomes
Eosomes
are innovative self-assembling nanobiologic particles composed of a
recombinant polypeptide and a therapeutic payload. The recombinant
polypeptide is designed to incorporate three functional domains for cell
targeting, active endosomal escape, and therapeutic payload binding. The
modular design of the polypeptide provides significant versatility in
adapting the application of the Eosomes to multiple disease areas and
therapeutic modalities. To date, Eos has generated two forms of Eosomes,
one targeting HER3 and one targeting c-Met. Expression of both cell
surface receptors is upregulated on metastatic and drug-resistant solid
tumors.
About Eos Biosciences, Inc.
Eos
Biosciences Inc.
is a bio-targeted nanomedicines company based in
Los Angeles, California with a worldwide and exclusive license from
Cedars-Sinai Medical Center to the intellectual property and know how
covering the Eosomes drug-targeting and delivery platform technology.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171017005662/en/
Contact:
Eos Biosciences, Inc.
Thomas Plotts, +1 424-253-1186
Chief
Financial Officer
Thomas.plotts@eosbiosciences.com
www.eosbiosciences.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CO-ANGLOGOLD-ASHANTI-PLC19.3.2024 12:05:35 CET | Press release
AngloGold Ashanti Releases Preliminary Unaudited Condensed Consolidated Financial Statements as of and for the Six Months and the Year Ended 31 December 2023
NY-IFF19.3.2024 11:46:34 CET | Press release
IFF Announces Sale of its Pharma Solutions Business to Roquette
PUMA19.3.2024 10:01:32 CET | Press release
“Unfortunately, not a lot has changed for girls in football.”
MOOVE19.3.2024 09:02:26 CET | Press release
Moove secures USD $100 million Series B round
WI-CIELO19.3.2024 08:12:25 CET | Press release
Cielo Debuts First Generative AI for Talent Acquisition: CLO.ai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom